EU orphan status for Cell Medica drug

Post Date: 
21 July 2016

ondon, UK-based Cell Medica has received European Commission orphan drug designations for its lead cancer immunotherapy CMD-003 (baltaleucel-T).

The designation relates to the treatment for extranodal NK/T-cell lymphoma, a rare type of non-Hodgkin lymphoma, and post-transplant lymphoproliferative disorder, a condition caused by B-cell proliferation due to therapeutic immunosuppression after organ transplantation.

CMD-003 is made of the patient's immune cells which have been activated to kill malignant cells expressing antigens associated with the oncogenic Epstein Barr virus (EBV).

Read more here